Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve
Apixaban, Warfarin, and On-X Mechanical Aortic ValvesAlthough vitamin K antagonists are the only oral anticoagulants approved with mechanical heart valves, this trial examined whether apixaban could be safely used in patients with an On-X mechanical aortic valve. A total of 863 such patients were assigned apixaban 5 mg twice daily or warfarin (target international normalized ratio 2.0 to 3.0). A total of 20 thrombotic events occurred in the apixaban group (4.2%/patient-year) and 6 events in the warfarin group (1.3%/patient-year). Major bleeding rates were 3.6%/patient-year with apixaban and 4.5%/patient-year with warfarin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
NEJM evidence - 2(2023), 7 vom: 01. Juli, Seite EVIDoa2300067 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Tracy Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3Z9Y7UWC1J |
|---|
| Anmerkungen: |
Date Completed 10.02.2024 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1056/EVIDoa2300067 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368095525 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368095525 | ||
| 003 | DE-627 | ||
| 005 | 20240211232016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/EVIDoa2300067 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM368095525 | ||
| 035 | |a (NLM)38320162 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Tracy Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Apixaban, Warfarin, and On-X Mechanical Aortic ValvesAlthough vitamin K antagonists are the only oral anticoagulants approved with mechanical heart valves, this trial examined whether apixaban could be safely used in patients with an On-X mechanical aortic valve. A total of 863 such patients were assigned apixaban 5 mg twice daily or warfarin (target international normalized ratio 2.0 to 3.0). A total of 20 thrombotic events occurred in the apixaban group (4.2%/patient-year) and 6 events in the warfarin group (1.3%/patient-year). Major bleeding rates were 3.6%/patient-year with apixaban and 4.5%/patient-year with warfarin | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a apixaban |2 NLM | |
| 650 | 7 | |a 3Z9Y7UWC1J |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 700 | 1 | |a Svensson, Lars G |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Vekstein, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Gerdisch, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Vijay U |e verfasserin |4 aut | |
| 700 | 1 | |a Moront, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Doug |e verfasserin |4 aut | |
| 700 | 1 | |a Lopes, Renato D |e verfasserin |4 aut | |
| 700 | 1 | |a Chavez, Alma |e verfasserin |4 aut | |
| 700 | 1 | |a Ruel, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Blackstone, Eugene H |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Richard C |e verfasserin |4 aut | |
| 700 | 1 | |a Thourani, Vinod |e verfasserin |4 aut | |
| 700 | 1 | |a Puskas, John |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Khalidi, Hussein R |e verfasserin |4 aut | |
| 700 | 1 | |a Cable, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Elefteriades, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Pochettino, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfe, J Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Graeve, Allen |e verfasserin |4 aut | |
| 700 | 1 | |a Sultan, Ibrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Sabe, Ashraf A |e verfasserin |4 aut | |
| 700 | 1 | |a Michelena, Hector I |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, John H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NEJM evidence |d 2022 |g 2(2023), 7 vom: 01. Juli, Seite EVIDoa2300067 |w (DE-627)NLM339641495 |x 2766-5526 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:EVIDoa2300067 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/EVIDoa2300067 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2023 |e 7 |b 01 |c 07 |h EVIDoa2300067 | ||